Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 satoreotide - Ipsen

Next Previous
X
Search
Drug Profile

Gallium-68 satoreotide - Ipsen

Alternative Names: 68Ga-satoreotide trizoxetan; 68Ga IPN 1070; 68Ga-DOTA-JR11; 68Ga-OPS-202; 68Ga-satoreotide; Gallium-68 satoreotide trixozetan; Satoreotide trizoxetan; SOMscan

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Ipsen
  • Class Imaging agents; Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours
  • No development reported Breast cancer

Most Recent Events

  • 30 Nov 2022 Gallium-68 satoreotide is still in phase II trial for Neuroendocrine tumours (Diagnosis) in Austria, Netherlands, Denmark and USA (IV) (EudraCT2016-004928-39) (NCT03220217)
  • 30 Nov 2022 No development reported - Phase-II for Breast cancer (Diagnosis) in Austria (IV)
  • 02 Mar 2020 Ipsen terminates a phase I/II trial in Small cell lung cancer and Breast cancer (Diagnosis, Second-line therapy, Combination therapy, Metastatic disease, Late-stage disease) in USA, United Kingdom, Germany, France, Belgium, Austria, and Switzerland (NCT03773133)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top